
National Research Corporation NRC
$ 18.75
0.11%
Quarterly report 2026-Q1
added 05-06-2026
National Research Corporation Operating Income 2011-2026 | NRC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income National Research Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.6 M | 35.2 M | 40 M | 46.5 M | 50.3 M | 42.7 M | 43 M | 35.3 M | 34.2 M | 31.2 M | 26.4 M | 28.3 M | 24.8 M | 22.7 M | 18.7 M | 13.9 M | 13.7 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 50.3 M | 13.7 M | 31.2 M |
Quarterly Operating Income National Research Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.57 M | 7.74 M | 1.59 M | 8.6 M | - | 7.98 M | 8.86 M | 8.76 M | - | 9.96 M | 9.36 M | 9.02 M | - | 11.1 M | 11.5 M | 11.7 M | - | 13.1 M | 12.2 M | 12 M | - | 12 M | 9.28 M | 11.2 M | - | 10.2 M | 10.1 M | 10.7 M | - | 9.17 M | 7.76 M | 8.96 M | - | 7.12 M | 8.45 M | 9.98 M | - | 7.34 M | 7.02 M | 8.01 M | - | 6.55 M | 6.36 M | 5.83 M | - | 7.16 M | 6.32 M | 8.4 M | - | 6.03 M | 5.53 M | 7.22 M | - | 5.65 M | 5.22 M | 6.08 M | - | 4.19 M | 3.83 M | 5.7 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 13.1 M | 1.59 M | 8.19 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M | ||
|
Fulgent Genetics
FLGT
|
-73.9 M | $ 15.96 | 5.63 % | $ 483 M | ||
|
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.76 | 1.09 % | $ 177 M | ||
|
Castle Biosciences
CSTL
|
-42.8 M | $ 19.83 | 3.07 % | $ 575 M | ||
|
Agilent Technologies
A
|
1.35 B | $ 115.62 | -2.55 % | $ 35.1 B | ||
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-7.91 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | ||
|
CareDx, Inc
CDNA
|
-30.8 M | $ 21.82 | 1.77 % | $ 1.16 B | ||
|
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
311 M | $ 93.06 | 2.26 % | $ 6.28 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | ||
|
Medpace Holdings
MEDP
|
535 M | $ 424.0 | -1.1 % | $ 12.2 B | ||
|
Co-Diagnostics
CODX
|
-50.2 M | $ 2.53 | 31.09 % | $ 3.37 M | ||
|
Myriad Genetics
MYGN
|
-387 M | $ 4.29 | 4.89 % | $ 397 M | ||
|
NeoGenomics
NEO
|
-116 M | $ 8.96 | -1.21 % | $ 1.15 B | ||
|
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | ||
|
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | ||
|
Natera
NTRA
|
-541 M | $ 194.24 | -11.64 % | $ 19.1 B | ||
|
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
25.2 M | $ 177.62 | -2.23 % | $ 8.8 B | ||
|
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | ||
|
Koninklijke Philips N.V.
PHG
|
1.42 B | $ 27.21 | 0.18 % | $ 25.8 B | ||
|
Exact Sciences Corporation
EXAS
|
-206 M | - | - | $ 19.8 B | ||
|
Personalis
PSNL
|
-88.1 M | $ 5.98 | -0.17 % | $ 534 M | ||
|
Guardant Health
GH
|
-437 M | $ 95.7 | 3.73 % | $ 12 B | ||
|
Senseonics Holdings
SENS
|
-68.3 M | $ 5.03 | -6.16 % | $ 210 M | ||
|
Soleno Therapeutics
SLNO
|
9.41 M | $ 52.95 | - | $ 2.69 B | ||
|
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
1.1 B | $ 124.49 | -0.41 % | $ 10.3 B | ||
|
Illumina
ILMN
|
-833 M | $ 141.88 | 2.29 % | $ 22.6 B | ||
|
Interpace Biosciences
IDXG
|
4.08 M | $ 1.95 | -2.5 % | $ 8.63 M | ||
|
QIAGEN N.V.
QGEN
|
466 M | - | - | $ 10.6 B | ||
|
Trinity Biotech plc
TRIB
|
-21.2 M | $ 0.61 | 2.52 % | $ 219 M | ||
|
Twist Bioscience Corporation
TWST
|
-136 M | $ 56.85 | -2.89 % | $ 3.4 B | ||
|
Biomerica
BMRA
|
-5.14 M | $ 2.15 | -2.05 % | $ 4.94 M | ||
|
Thermo Fisher Scientific
TMO
|
7.75 B | $ 465.0 | -1.99 % | $ 175 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.38 B | $ 254.12 | -1.52 % | $ 21.1 B | ||
|
Celcuity
CELC
|
-172 M | $ 131.06 | 0.27 % | $ 6.13 B | ||
|
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | ||
|
Waters Corporation
WAT
|
271 M | $ 355.13 | 1.32 % | $ 21.1 B | ||
|
Neogen Corporation
NEOG
|
-1.06 B | $ 9.05 | -2.16 % | $ 1.96 B | ||
|
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 187.39 | -1.82 % | $ 20.8 B |